MA-ROCHESTER-ELECTRONICS
25.3.2024 15:01:26 CET | Business Wire | Press release
Rochester Electronics, LLC and Intelligent Memory have joined forces to ensure the continued availability of mature and legacy DRAM and NAND storage solutions tailored for industrial and embedded applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240325645193/en/
Rochester Electronics and Intelligent Memory Ensure the Availability of Legacy Storage Solutions (Photo: Business Wire)
Intelligent Memory has been the trusted provider of reliable and high-quality memory products for over three decades, serving and fulfilling the enduring, shifting needs of industrial applications. In a landscape where leading-edge memory manufacturers no longer focus on supporting legacy memories, customers with end-of-life microprocessors still require low-density storage solutions. Intelligent Memory is one of the few memory manufacturers that offers DRAM components as well as DRAM modules ranging from SDRAM to DDR5 in addition to its customizable NAND flash memory portfolio, making IM’s portfolio one of the most comprehensive offerings in the market from one single source.
Rochester Electronics is the world’s largest continuous source of semiconductors, offering 100% authorized, traceable, certified, and guaranteed devices. Rochester is focused on extending the availability of obsolete lifecycle products, along with providing support for active lifecycle products.
Rochester Electronics supports mature densities with a stock of core microprocessor components. Rochester stocks an extensive portfolio of processors, including continued production of numerous legacy and end-of-life processors through licensing, die banks, and die product replications. Customers are now able to purchase a range of Intelligent Memory devices, including DRAM, non-volatile NAND/SLC NAND, and low-density eMMC products, through Rochester. The partnership between Rochester and Intelligent Memory supports mutually valued customers across the globe.
“For over forty years, Rochester has been providing support for legacy and mature semiconductor technologies. Intelligent Memory’s diverse range of mature and legacy DRAM and NAND offerings perfectly align with our strategic vision, enabling seamless continuity and longevity in Memory technology for our valued global customers.”
- Paul Mason, Global Technology Director (Memory), Rochester Electronics
“With our portfolio of reliable legacy memory solutions tailored specifically to the needs of industrial customers, we help Rochester address the needs of many of its customers without costly and time-consuming re-designs and qualifications.”
- David Raquet, Global Vice President Sales and Marketing, Intelligent Memory
About Intelligent Memory
Intelligent Memory has been developing memory products for demanding industrial applications since 1991 (as Pacific Force Technology Limited until 2013). The extensive product portfolio consists of DRAM ICs and modules (from SDRAM to DDR5 as well as LPDDR4(x) components) and a variety of managed NAND products for industrial applications. All solutions of Intelligent Memory have been designed to meet the industry’s demands for quality, reliability, longevity, and long-term availability.
For more information visit: www.intelligentmemory.com
About Rochester Electronics
Rochester Electronics is the world’s largest continuous source of semiconductors–100% Authorized by over 70 leading semiconductor manufacturers.
As an original manufacturer stocking distributor, Rochester has over 15 billion devices in stock encompassing more than 200,000-part numbers, providing the world’s most extensive range of end-of-life (EOL) semiconductors and the broadest range of active semiconductors.
As a licensed semiconductor manufacturer, Rochester has manufactured over 20,000 device types. With over 12 billion die in stock, Rochester has the capability to manufacture over 70,000 device types.
Rochester offers a full range of manufacturing services including Design, Wafer Storage and Processing, Assembly, Test, and Reliability, providing single solutions through to full turnkey manufacturing.
Rochester is the Semiconductor Lifecycle Solution. No other company compares to the breadth of Rochester’s product selection, value-added services, and manufacturing solutions.
With direct sales and support staff in all major markets, complemented by a network of regional and global authorized channel partners, we aim to meet your needs over the phone or via our e-commerce platforms anytime, anywhere.
For more information visit: www.rocelec.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325645193/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
